Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free TRAW Stock Alerts

Traws Pharma (TRAW) Financials

Traws Pharma logo
$0.66 0.00 (-0.45%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Traws Pharma

Annual Income Statements for Traws Pharma

This table shows Traws Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -64 -24 -20 -24 -21 -22 -25 -16 -19 -19 6.87
Consolidated Net Income / (Loss)		 -64 -24 -20 -24 -20 -22 -25 -16 -19 -19 9.17
Net Income / (Loss) Continuing Operations		 -64 -24 -20 -24 -20 -22 -25 -16 -19 -19 9.17
Total Pre-Tax Income 		-64 -24 -20 -24 -21 -21 -25 -16 -19 -20 8.69
Total Operating Income		 -64 -24 -24 -26 -23 -22 -25 -16 -20 -20 -18
Total Gross Profit		 0.80 11 5.55 0.79 1.23 2.18 0.23 0.23 0.23 0.23 2.79
Total Revenue		 0.80 11 5.55 0.79 1.23 2.18 0.23 0.23 0.23 0.23 2.79
Operating Revenue		 0.80 11 5.55 0.79 1.23 2.18 0.23 0.23 0.23 0.23 2.79
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 65 35 29 27 25 24 25 17 20 21 21
Selling, General & Admin Expense		 15 9.53 9.18 7.41 7.59 8.35 8.33 9.43 8.45 9.09 8.52
Research & Development Expense		 49 26 20 19 17 16 17 7.30 11 11 12
Total Other Income / (Expense), net		 0.02 0.00 3.99 1.63 2.75 0.21 -0.21 0.32 0.66 0.00 27
Other Income / (Expense), net		 0.02 - 3.99 1.63 2.75 0.21 -0.21 0.32 0.66 - 27
Other Gains / (Losses), net		 -0.05 -0.04 0.06 0.03 - - 0.05 0.01 - 1.35 0.48
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.11 -0.04 - - 0.16 - - - - 0.00 2.31
Basic Earnings per Share		 ($2.94) ($10.54) ($4.44) ($40.15) ($4.99) ($1.49) ($2.17) ($0.96) ($0.91) ($22.57) $0.83
Weighted Average Basic Shares Outstanding		 21.65M 2.27M 4.43M 600.02K 4.12M 14.38M 11.60M 16.83M 20.91M 839.55K 8.23M
Diluted Earnings per Share		 ($2.94) ($10.54) ($4.44) ($40.15) ($4.99) ($1.49) ($2.17) ($0.96) ($0.91) ($22.57) $0.82
Weighted Average Diluted Shares Outstanding		 21.65M 2.27M 4.43M 600.02K 4.12M 14.38M 11.60M 16.83M 20.91M 839.55K 8.38M
Weighted Average Basic & Diluted Shares Outstanding		 21.65M 2.27M 4.43M 600.02K 4.12M 14.38M 174.04M 20.90M 20.97M 0.00 13.81K

Quarterly Income Statements for Traws Pharma

This table shows Traws Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.74 -4.18 -4.98 -21 -1.43 34 15 -0.63 -3.04 -5.69
Consolidated Net Income / (Loss)		 -4.74 -4.18 -4.98 -123 -8.48 146 21 -0.92 -3.96 -7.11
Net Income / (Loss) Continuing Operations		 -4.74 -4.18 -4.98 -123 -8.48 146 21 -0.92 -3.96 -7.11
Total Pre-Tax Income 		-4.74 -5.53 -4.98 -123 -8.54 146 21 -1.10 -4.06 -7.11
Total Operating Income		 -5.09 -4.46 -5.21 -123 -8.54 119 -5.20 -1.25 -4.06 -6.95
Total Gross Profit		 0.06 0.06 0.06 0.06 0.06 2.62 0.06 2.73 0.00 0.00
Total Revenue		 0.06 0.06 0.06 0.06 0.06 2.62 0.06 2.73 0.00 0.00
Operating Revenue		 0.06 0.06 0.06 0.06 0.06 2.62 0.06 2.73 0.00 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.15 4.52 5.27 123 8.59 -117 5.26 3.98 4.06 6.95
Selling, General & Admin Expense		 2.69 2.08 3.36 1.98 3.48 -0.29 2.75 1.69 1.74 2.03
Research & Development Expense		 2.46 2.43 1.91 121 5.11 -116 2.51 2.29 2.31 4.91
Total Other Income / (Expense), net		 0.35 -1.07 0.23 0.00 0.00 26 27 0.15 -0.00 -0.16
Other Income / (Expense), net		 0.35 - 0.23 0.00 0.00 26 27 0.15 -0.00 -0.16
Other Gains / (Losses), net		 - - - 0.21 0.06 - 0.18 0.19 0.10 -0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 -102 -7.04 112 6.41 -0.29 -0.93 -1.42
Basic Earnings per Share		 ($5.64) ($4.98) ($5.92) ($20.52) ($1.49) $4.14 $2.17 ($0.11) ($0.34) ($0.53)
Weighted Average Basic Shares Outstanding		 840.12K 839.55K 841.74K 1.01M 961.53K 8.23M 6.97M 5.82M 8.82M 10.64M
Diluted Earnings per Share		 ($5.64) ($4.98) ($5.92) ($20.52) ($1.49) $4.14 $2.09 ($0.11) ($0.34) ($0.53)
Weighted Average Diluted Shares Outstanding		 840.12K 839.55K 841.74K 1.01M 961.53K 8.38M 7.22M 5.82M 8.82M 10.64M
Weighted Average Basic & Diluted Shares Outstanding		 21.00M 0.00 0.00 24.95K 23.63K 13.81K 14.80K 13.52K 13.47K 13.47K

Annual Cash Flow Statements for Traws Pharma

This table details how cash moves in and out of Traws Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -16 -24 1.60 -17 13 5.76 -3.70 36 -16 -18 0.52
Net Cash From Operating Activities		 -58 -31 -16 -24 -23 -21 -23 -19 -16 -18 -30
Net Cash From Continuing Operating Activities		 -58 -31 -16 -24 -23 -21 -23 -19 -16 -18 -30
Net Income / (Loss) Continuing Operations		 -64 -24 -20 -24 -20 -22 -25 -16 -19 -19 -167
Consolidated Net Income / (Loss)		 -64 -24 -20 -24 -20 -22 -25 -16 -19 -19 -167
Depreciation Expense		 0.43 0.15 0.10 0.09 0.06 0.01 0.01 0.01 0.01 0.02 0.01
Non-Cash Adjustments To Reconcile Net Income		 5.05 3.69 -0.06 0.08 -1.27 0.99 0.58 0.26 1.17 1.30 143
Changes in Operating Assets and Liabilities, net		 0.67 -11 3.82 0.10 -1.07 -0.42 1.49 -3.59 1.48 -0.30 -6.57
Net Cash From Investing Activities		 40 0.00 0.00 0.00 0.00 -0.06 -0.02 0.00 0.00 -0.01 -3.65
Net Cash From Continuing Investing Activities		 40 0.00 0.00 0.00 0.00 -0.06 -0.02 0.00 0.00 -0.01 -3.65
Purchase of Property, Plant & Equipment		 -0.23 - - - - -0.06 -0.02 - 0.00 -0.01 -3.65
Net Cash From Financing Activities		 1.46 7.46 17 6.36 36 27 19 56 0.00 0.00 34
Net Cash From Continuing Financing Activities		 1.46 7.46 17 6.36 36 27 19 56 0.00 0.00 34
Repurchase of Common Equity		 - - - - - - - - - - 0.00
Issuance of Common Equity		 0.50 7.46 17 6.36 35 22 9.06 55 - 0.00 34
Other Financing Activities, net		 0.96 - 0.00 - 0.59 4.85 10 0.52 - - 0.00
Effect of Exchange Rate Changes		 -0.01 -0.01 -0.01 - - - 0.03 -0.03 -0.02 0.01 -0.02

Quarterly Cash Flow Statements for Traws Pharma

This table details how cash moves in and out of Traws Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.49 -4.42 -4.43 0.50 -11 16 -5.40 -2.86 -6.66 -0.69
Net Cash From Operating Activities		 -4.47 -4.43 -4.42 -9.85 -11 -4.04 -5.44 -5.98 -4.01 -2.58
Net Cash From Continuing Operating Activities		 -4.47 -4.43 -4.42 -9.85 -11 -4.04 -5.44 -5.98 -4.01 -2.58
Net Income / (Loss) Continuing Operations		 -4.74 -4.18 -4.98 -123 -8.48 -30 21 -0.92 -3.96 -7.11
Consolidated Net Income / (Loss)		 -4.74 -4.18 -4.98 -123 -8.48 -30 21 -0.92 -3.96 -7.11
Depreciation Expense		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.04
Non-Cash Adjustments To Reconcile Net Income		 0.36 0.33 0.33 118 0.34 25 -26 -0.04 0.14 0.79
Changes in Operating Assets and Liabilities, net		 -0.10 -0.58 0.22 -4.56 -3.35 1.11 -0.58 -5.02 -0.20 3.69
Net Cash From Investing Activities		 -0.01 - 0.00 -3.65 - - 0.00 - -2.59 0.00
Net Cash From Continuing Investing Activities		 -0.01 - 0.00 -3.65 - - 0.00 - -2.59 0.00
Net Cash From Financing Activities		 - - 0.00 14 - 20 0.01 3.10 -0.06 1.90
Net Cash From Continuing Financing Activities		 - - 0.00 14 - 20 0.01 3.10 -0.06 1.90
Repurchase of Common Equity		 - - 0.00 - - - -0.12 -0.16 -0.18 0.00
Issuance of Common Equity		 - - 0.00 14 - 20 0.12 3.26 0.12 1.90
Other Financing Activities, net		 - - 0.00 - - - 0.01 0.00 - 0.00
Effect of Exchange Rate Changes		 - 0.01 -0.01 -0.00 - -0.01 0.02 0.03 - -0.01

Annual Balance Sheets for Traws Pharma

This table presents Traws Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2025
Total Assets		 23 23 4.98 18 24 20 55 39 23 11 11
Total Current Assets		 23 23 4.90 18 23 20 55 39 23 7.98 7.98
Cash & Equivalents		 20 21 4.02 17 23 19 55 39 21 3.82 3.82
Accounts Receivable		 1.50 0.03 0.06 0.04 0.10 0.04 0.03 0.03 0.02 3.79 3.79
Prepaid Expenses		 1.83 1.59 0.82 0.76 0.65 0.72 0.33 0.56 1.82 0.37 0.37
Plant, Property, & Equipment, net		 0.25 0.15 0.06 0.01 0.05 0.05 0.04 0.02 0.02 0.01 0.01
Total Noncurrent Assets		 0.01 0.01 0.01 0.15 0.15 0.15 0.01 0.00 0.00 2.63 2.63
Intangible Assets		 - - - - - - - - - 2.53 2.53
Other Noncurrent Operating Assets		 0.01 0.01 0.01 0.15 0.15 0.15 0.01 0.00 0.00 0.10 0.10
Total Liabilities & Shareholders' Equity		 23 23 4.98 18 24 20 55 39 23 11 11
Total Liabilities		 13 18 16 13 12 14 9.36 11 12 11 11
Total Current Liabilities		 7.61 10 9.98 8.44 8.29 10 6.12 8.05 9.22 11 11
Accounts Payable		 3.42 5.32 6.19 4.04 4.27 4.83 2.76 3.86 5.62 5.65 5.65
Accrued Expenses		 3.73 4.38 3.34 4.17 3.80 4.96 3.13 3.96 3.38 5.49 5.49
Total Noncurrent Liabilities		 5.00 7.95 5.86 4.10 3.81 3.79 3.24 3.02 2.79 0.10 0.10
Other Noncurrent Operating Liabilities		 - 3.40 1.77 0.18 0.11 0.32 - - 0.00 0.10 0.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 11 5.13 -11 5.39 23 6.18 46 28 11 -0.63 -0.63
Total Preferred & Common Equity		 10 4.30 -12 5.39 0.00 6.18 46 28 11 -0.63 -0.63
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 10 4.30 -12 5.39 23 6.18 46 28 11 -0.63 -0.63
Common Stock		 329 343 351 387 415 435 491 492 493 639 639
Retained Earnings		 -319 -338 -362 -382 -403 -429 -445 -464 -483 -640 -640
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.03 0.00 -0.01 -0.02 0.01 -0.01 -0.03 -0.02 0.01 0.01

Quarterly Balance Sheets for Traws Pharma

This table presents Traws Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 27 18 19 8.94 19 16 12 8.16
Total Current Assets		 27 18 19 8.92 19 15 9.63 5.67
Cash & Equivalents		 25 16 17 5.41 16 13 6.42 3.13
Accounts Receivable		 0.02 0.02 0.02 2.12 1.65 1.32 1.99 1.69
Prepaid Expenses		 1.75 1.75 1.77 1.39 1.27 0.97 1.21 0.85
Plant, Property, & Equipment, net		 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.20 0.24 2.81 2.49
Intangible Assets		 - - - - - - 2.57 2.48
Other Noncurrent Operating Assets		 0.00 0.00 0.00 0.00 0.20 0.24 0.24 0.00
Total Liabilities & Shareholders' Equity		 27 18 19 8.94 19 16 12 8.16
Total Liabilities		 13 12 13 11 13 7.36 7.90 13
Total Current Liabilities		 9.67 9.42 9.91 8.35 10 7.35 7.89 13
Accounts Payable		 6.15 6.57 6.17 5.47 7.66 4.76 5.11 7.67
Accrued Expenses		 3.30 2.63 3.51 2.65 2.52 2.59 2.78 5.54
Total Noncurrent Liabilities		 2.85 2.74 2.68 2.62 2.66 0.01 0.01 0.26
Other Noncurrent Operating Liabilities		 - - - - 0.15 0.01 0.01 0.26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 6.02 -106 -2.03 6.00 8.26 4.55 -5.31
Total Preferred & Common Equity		 15 6.02 -106 -2.03 6.00 8.26 4.55 -5.31
Preferred Stock		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15 6.02 -106 -2.03 6.00 8.26 4.55 -5.31
Common Stock		 493 494 505 617 634 637 637 642
Retained Earnings		 -478 -488 -611 -619 -628 -629 -633 -647
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.03 -0.03 -0.03 -0.02 0.01 0.01 -0.00

Annual Metrics And Ratios for Traws Pharma

This table displays calculated financial ratios and metrics derived from Traws Pharma's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2025
DEI Shares Outstanding		 21,692,240.00 24,868,380.00 6,759,895.00 9,851,163.00 5,674,220.00 8,197,462.00 184,948,267.00 20,890,563.00 20,925,992.00 21,003,409.00 7,990,867.00
DEI Adjusted Shares Outstanding		 867,690.00 994,735.00 270,396.00 394,047.00 226,969.00 327,898.00 7,397,931.00 835,623.00 837,040.00 840,136.00 7,990,867.00
DEI Earnings Per Adjusted Shares Outstanding		 -73.39 -24.11 -72.73 -61.14 -90.64 -65.58 -3.40 -19.34 -22.66 -22.55 0.86
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -83.17% 1,332.00% -51.59% -85.81% 56.04% 77.77% -89.42% -2.16% 0.00% 0.00% 1,134.51%
EBITDA Growth		 -2.52% 62.36% 17.64% -22.44% 14.75% -4.88% -17.27% 35.84% -17.26% -7.03% 142.91%
EBIT Growth		 -2.48% 62.38% 17.76% -22.29% 14.83% -4.67% -17.25% 35.82% -17.24% -7.03% 142.82%
NOPAT Growth		 -2.45% 62.39% 1.12% -8.58% 9.54% 6.80% -15.18% 34.00% -18.98% -3.42% -25.80%
Net Income Growth		 -1.98% 62.34% 18.13% -22.50% 15.28% -5.36% -16.99% 35.75% -17.33% 0.08% 148.40%
EPS Growth		 51.96% 62.34% 57.87% -22.50% 87.57% 70.14% -16.99% 55.76% 5.21% 0.08% 103.63%
Operating Cash Flow Growth		 6.09% 45.81% 49.38% -50.64% 4.72% 8.22% -10.77% 15.55% 16.39% -10.05% -66.14%
Free Cash Flow Firm Growth		 30.50% 36.35% 66.69% -109.68% -0.75% 20.30% -1.13% 2.22% 20.76% -18.52% -62.50%
Invested Capital Growth		 -4.46% 55.15% -81.19% 8.81% 22.18% 3.72% -15.23% 30.35% -16.74% 2.86% 56.16%
Revenue Q/Q Growth		 -69.42% 480.64% -62.95% -3.67% -6.40% -1.31% 13.24% -0.44% 0.00% 0.00% 1,134.51%
EBITDA Q/Q Growth		 1.73% 40.92% -40.88% -3.19% 3.08% -0.61% -47.62% 38.31% -7.41% 5.90% 106.15%
EBIT Q/Q Growth		 1.76% 40.87% -40.59% -3.16% 3.10% -0.58% -47.59% 38.29% -7.41% 5.90% 106.14%
NOPAT Q/Q Growth		 1.85% 40.87% -69.03% 1.35% -0.13% 1.90% -2.16% 13.12% -11.16% 5.90% 81.96%
Net Income Q/Q Growth		 1.90% 40.84% -78.34% -3.25% 2.65% -0.45% 21.06% -41.37% -9.57% 6.12% 106.51%
EPS Q/Q Growth		 1.67% 40.84% -118.72% -3.25% -34.14% 57.31% 21.06% -33.33% -9.64% 6.12% 102.51%
Operating Cash Flow Q/Q Growth		 4.73% 22.81% 4.11% -1.32% -3.35% 0.23% -0.47% 5.81% 2.28% -3.14% 1.29%
Free Cash Flow Firm Q/Q Growth		 0.00% 13.33% 23.02% 4.39% -6.06% 3.25% 1.30% 0.74% 4.59% -6.56% 76.97%
Invested Capital Q/Q Growth		 7.91% 50.09% -3.23% -8.43% -0.51% -2.67% -7.24% 7.85% -13.05% 5.39% 40.23%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -7,912.00% -207.94% -353.75% -3,052.22% -1,667.67% -983.92% -10,903.90% -7,150.89% -8,384.96% -8,974.34% 311.97%
Operating Margin		 -7,968.00% -209.25% -427.39% -3,270.27% -1,895.93% -994.00% -10,819.48% -7,299.12% -8,684.51% -8,981.42% -640.68%
EBIT Margin		 -7,965.50% -209.25% -355.48% -3,063.41% -1,672.15% -984.56% -10,909.52% -7,157.08% -8,391.15% -8,981.42% 311.54%
Profit (Net Income) Margin		 -7,974.38% -209.70% -354.62% -3,061.25% -1,662.05% -985.02% -10,890.48% -7,151.77% -8,391.15% -8,384.07% 328.67%
Tax Burden Percent		 100.03% 100.07% 100.07% 100.05% 99.40% 100.05% 100.02% 99.93% 100.00% 93.35% 105.50%
Interest Burden Percent		 100.08% 100.15% 99.69% 99.88% 100.00% 100.00% 99.81% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -122.07% -139.42% -246.35% 840.32% 745.71% -150.71% -171.59% -61.81% -50.96% -97.22% 182.61%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -83.58% -67.73% -84.47% -170.91% -179.32% -103.34% -115.44% -42.87% -39.99% -65.42% 52.20%
Return on Assets (ROA)		 -83.67% -67.88% -84.27% -170.79% -178.24% -103.39% -115.24% -42.84% -39.99% -61.07% 55.08%
Return on Common Equity (ROCE)		 -120.48% -132.52% -220.73% 1,083.59% 858.78% -150.71% -171.59% -61.81% -50.96% -97.22% 182.61%
Return on Equity Simple (ROE_SIMPLE)		 -280.44% -239.99% -457.69% 206.07% -378.88% 0.00% -407.40% -35.05% -66.99% -177.55% 0.00%
Net Operating Profit after Tax (NOPAT)		 -45 -17 -17 -18 -16 -15 -17 -12 -14 -14 -18
NOPAT Margin		 -5,577.60% -146.48% -299.17% -2,289.19% -1,327.15% -695.80% -7,573.64% -5,109.38% -6,079.16% -6,286.99% -640.68%
Net Nonoperating Expense Percent (NNEP)		 -26.66% -22.79% -14.89% -47.70% -39.18% -24.63% -28.74% -12.46% -11.14% -15.91% 219.51%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -133.14% 2,841.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,889.88% 83.21% 165.49% 940.91% 617.75% 382.27% 3,604.33% 4,170.35% 3,737.61% 4,023.89% 305.45%
R&D to Revenue		 6,178.13% 226.04% 361.90% 2,429.35% 1,378.18% 711.73% 7,315.15% 3,228.76% 5,046.90% 5,057.52% 435.23%
Operating Expenses to Revenue		 8,068.00% 309.25% 527.39% 3,370.27% 1,995.93% 1,094.00% 10,919.48% 7,399.12% 8,784.51% 9,081.42% 740.68%
Earnings before Interest and Taxes (EBIT)		 -64 -24 -20 -24 -21 -21 -25 -16 -19 -20 8.69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -63 -24 -20 -24 -20 -21 -25 -16 -19 -20 8.70
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 7,058.94 5,348.32 803.49 0.00 33.34 2.03 209.27 1.16 0.48 1.47 0.00
Price to Tangible Book Value (P/TBV)		 7,058.94 5,348.32 803.49 0.00 33.34 2.03 209.27 1.16 0.48 1.47 0.00
Price to Revenue (P/Rev)		 200,721.01 4,673.24 622.54 4,224.61 146.25 21.57 5,594.08 235.71 59.79 69.29 3.24
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.32
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 76.03%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 200,667.47 4,671.58 618.82 4,220.55 132.43 11.16 5,511.73 0.00 0.00 0.00 1.87
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.60
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.60
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.38 -1.84 -2.59 4.44 3.84 -1.80 -1.82 -1.42 -1.26 -1.53 -2.45
Leverage Ratio		 1.46 2.05 2.92 -4.92 -4.18 1.46 1.49 1.44 1.27 1.59 3.32
Compound Leverage Factor		 1.46 2.06 2.91 -4.91 -4.18 1.46 1.49 1.44 1.27 1.59 3.32
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 3.70% 7.66% 16.19% -7.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 96.30% 92.34% 83.81% 107.64% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4,050.46 2,527.24 92.14 7.02 -24.32 -23.65 22.56 -7.70 -16.38 -31.24 -81.30
Noncontrolling Interest Sharing Ratio		 1.30% 4.94% 10.40% -28.95% -15.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.57 3.05 2.27 0.49 2.11 2.83 1.97 9.06 4.89 2.46 0.72
Quick Ratio		 4.26 2.80 2.11 0.41 2.02 2.75 1.90 9.01 4.82 2.26 0.68
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -44 -28 -9.28 -19 -20 -16 -16 -15 -12 -15 -24
Operating Cash Flow to CapEx		 -25,284.21% 0.00% 0.00% 0.00% 0.00% -37,874.55% -153,833.33% 0.00% 0.00% -128,085.71% -816.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.32 0.24 0.06 0.11 0.11 0.01 0.01 0.00 0.01 0.17
Accounts Receivable Turnover		 0.00 14.00 7.23 17.49 26.13 32.83 3.42 6.95 7.93 9.62 1.46
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.53 34.30 27.73 7.29 33.64 74.00 4.53 5.02 7.29 9.83 192.41
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 26.06 50.51 20.87 13.97 11.12 106.66 52.49 46.03 37.95 249.35
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 26.06 50.51 20.87 13.97 11.12 106.66 52.49 46.03 37.95 249.35
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -20 -9.01 -16 -15 -12 -11 -13 -8.95 -10 -10 -4.45
Invested Capital Turnover		 -0.04 -0.79 -0.44 -0.05 -0.09 -0.19 -0.02 -0.02 -0.02 -0.02 -0.38
Increase / (Decrease) in Invested Capital		 -0.86 11 -7.31 1.44 3.30 0.43 -1.70 3.90 -1.50 0.30 5.70
Enterprise Value (EV)		 160,534 53,518 3,432 3,322 163 24 1,273 -1.80 -25 -5.16 5.21
Market Capitalization		 160,577 53,537 3,453 3,325 180 47 1,292 53 14 16 9.03
Book Value per Share		 $1.05 $0.40 $0.64 ($1.19) $0.95 $2.82 $0.03 $2.21 $1.35 $0.51 ($0.08)
Tangible Book Value per Share		 $1.05 $0.40 $0.64 ($1.19) $0.95 $2.82 $0.03 $2.21 $1.35 $0.51 ($0.40)
Total Capital		 24 11 5.13 -11 5.39 23 6.18 46 28 11 -0.63
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -44 -20 -21 -4.02 -17 -23 -19 -55 -39 -21 -3.82
Capital Expenditures (CapEx)		 0.23 0.00 0.00 0.00 0.00 0.06 0.02 0.00 0.00 0.01 3.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.06 -4.27 -8.54 -9.10 -7.64 -7.54 -9.26 -5.76 -7.46 -7.38 -6.99
Debt-free Net Working Capital (DFNWC)		 37 16 13 -5.07 9.33 15 9.76 49 31 13 -3.17
Net Working Capital (NWC)		 37 16 13 -5.07 9.33 15 9.76 49 31 13 -3.17
Net Nonoperating Expense (NNE)		 19 7.24 3.07 6.08 4.11 6.31 7.66 4.62 5.23 4.74 -27
Net Nonoperating Obligations (NNO)		 -44 -20 -21 -4.02 -17 -34 -19 -55 -39 -21 -3.82
Total Depreciation and Amortization (D&A)		 0.43 0.15 0.10 0.09 0.06 0.01 0.01 0.01 0.01 0.02 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -882.63% -37.26% -154.00% -1,155.91% -622.39% -345.58% -4,009.52% -2,546.46% -3,299.12% -3,265.93% -250.43%
Debt-free Net Working Capital to Revenue		 4,580.75% 136.00% 232.76% -644.60% 759.53% 695.47% 4,226.41% 21,820.80% 13,850.00% 5,946.90% -113.51%
Net Working Capital to Revenue		 4,580.75% 136.00% 232.76% -644.60% 759.53% 695.47% 4,226.41% 21,820.80% 13,850.00% 5,946.90% -113.51%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.94) ($1.05) ($4.44) ($2.68) ($4.99) ($1.49) ($0.14) ($0.96) ($0.91) ($22.50) $0.83
Adjusted Weighted Average Basic Shares Outstanding		 21.70M 27.40M 6.77M 18.95M 5.90M 167.26M 236.61M 16.83M 20.91M 839.56K 8.23M
Adjusted Diluted Earnings per Share		 ($2.94) ($1.05) ($4.44) ($2.68) ($4.99) ($1.49) ($0.14) ($0.96) ($0.91) ($22.50) $0.82
Adjusted Weighted Average Diluted Shares Outstanding		 21.70M 27.40M 6.77M 18.95M 5.90M 167.26M 236.61M 16.83M 20.91M 839.56K 8.38M
Adjusted Basic & Diluted Earnings per Share		 ($2.94) ($1.05) ($4.44) ($2.68) ($4.99) ($1.49) ($0.14) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 21.65M 22.74M 4.43M 9.00M 4.12M 14.38M 174.04M 20.90M 20.97M 841.63K 13.81K
Normalized Net Operating Profit after Tax (NOPAT)		 -45 -17 -17 -18 -16 -15 -17 -12 -14 -14 -13
Normalized NOPAT Margin		 -5,577.60% -146.48% -299.17% -2,289.19% -1,327.15% -695.80% -7,573.64% -5,109.38% -6,079.16% -6,286.99% -448.48%
Pre Tax Income Margin		 -7,972.00% -209.56% -354.36% -3,059.59% -1,672.15% -984.56% -10,888.74% -7,157.08% -8,391.15% -8,981.42% 311.54%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Traws Pharma

This table displays calculated financial ratios and metrics derived from Traws Pharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 20,977,625.00 21,003,409.00 21,040,645.00 25,301,009.00 25,306,509.00 7,990,867.00 5,073,790.00 5,564,315.00 7,063,829.00 7,990,867.00
DEI Adjusted Shares Outstanding		 839,105.00 840,136.00 841,626.00 1,012,040.00 1,012,260.00 7,990,867.00 5,073,790.00 5,564,315.00 7,063,829.00 7,990,867.00
DEI Earnings Per Adjusted Shares Outstanding		 -5.65 -4.98 -5.92 -20.53 -1.42 4.26 2.97 -0.11 -0.43 -0.71
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 4,578.57% 1.79% 4,694.74% -100.00% -100.00%
EBITDA Growth		 16.03% 22.20% 13.74% -2,804.95% -80.27% 3,365.16% 528.02% 99.11% 52.62% -133.13%
EBIT Growth		 15.99% 22.18% 13.71% -2,802.31% -80.12% 3,362.19% 527.65% 99.11% 52.46% -133.34%
NOPAT Growth		 9.79% 22.18% 15.07% -2,575.66% -67.73% 3,917.03% -42.61% 98.99% 52.50% 6.55%
Net Income Growth		 12.21% 22.80% 13.71% -2,797.48% -78.84% 3,584.01% 531.27% 99.26% 53.25% -133.07%
EPS Growth		 12.21% 22.80% 13.71% -2,797.48% 73.58% 183.13% 135.30% 99.46% 77.18% -125.36%
Operating Cash Flow Growth		 -14.59% -14.06% 2.62% -119.42% -156.79% 8.80% -22.90% 39.31% 65.05% 52.62%
Free Cash Flow Firm Growth		 52.99% -36.04% -222.47% -19,312.94% -345.73% 3,417.00% -22.17% 92.08% 9.21% -12.66%
Invested Capital Growth		 -16.07% 2.86% 8.54% 0.41% 30.61% 56.16% 4.22% 55.33% 74.81% 15.02%
Revenue Q/Q Growth		 0.00% -1.75% 0.00% 1.79% 0.00% 4,496.49% -97.82% 4,694.74% -100.00% 0.00%
EBITDA Q/Q Growth		 -11.49% 5.83% -11.69% -2,377.28% 93.08% 1,805.66% -85.36% -105.17% -266.88% 0.00%
EBIT Q/Q Growth		 -11.51% 5.85% -11.68% -2,375.38% 93.08% 1,805.24% -85.36% -105.18% -267.91% 0.00%
NOPAT Q/Q Growth		 -10.39% 12.32% -16.81% -2,266.62% 93.08% 2,095.26% -104.36% 83.20% -224.66% 0.00%
Net Income Q/Q Growth		 -11.51% 11.71% -19.10% -2,371.26% 93.12% 1,820.01% -85.26% -104.26% -333.01% 0.00%
EPS Q/Q Growth		 -11.51% 11.71% -19.10% -2,371.26% 92.74% 377.85% -49.52% -105.26% -209.09% 0.00%
Operating Cash Flow Q/Q Growth		 0.47% 0.87% 0.14% -122.69% -16.48% 64.80% -34.58% -9.97% 32.92% 0.00%
Free Cash Flow Firm Q/Q Growth		 -366.81% -64.75% -34.92% -1,770.91% 89.28% 1,326.03% -104.97% -21.30% -22.86% 0.00%
Invested Capital Q/Q Growth		 0.96% 5.39% -2.23% -3.97% 31.00% 40.23% -123.35% 51.50% 61.09% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -8,305.26% -7,960.71% -8,891.07% -216,392.98% -14,971.93% 5,555.76% 37,387.72% -40.32% 0.00% 0.00%
Operating Margin		 -8,928.07% -7,967.86% -9,307.14% -216,400.00% -14,975.44% 4,550.42% -9,128.07% -45.70% 0.00% 0.00%
EBIT Margin		 -8,314.04% -7,967.86% -8,898.21% -216,400.00% -14,975.44% 5,555.69% 37,385.96% -40.36% 0.00% 0.00%
Profit (Net Income) Margin		 -8,314.04% -7,471.43% -8,898.21% -216,040.35% -14,868.42% 5,563.78% 37,701.75% -33.48% 0.00% 0.00%
Tax Burden Percent		 100.00% 75.61% 100.00% 99.83% 99.29% 100.15% 100.84% 82.96% 97.63% 100.03%
Interest Burden Percent		 100.00% 124.03% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -84.30% -97.22% -125.69% -1,096.52% -2,255.45% 182.61% 593.31% -248.20% -1,059.63% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -53.06% -58.04% -75.55% -1,989.93% -188.16% 930.95% 5,604.63% -6.83% 0.00% 0.00%
Return on Assets (ROA)		 -53.06% -54.42% -75.55% -1,986.62% -186.82% 932.31% 5,651.97% -5.67% 0.00% 0.00%
Return on Common Equity (ROCE)		 -84.30% -97.22% -125.69% 3,799.78% -2,255.45% 182.61% 593.31% 1,680.90% -1,059.63% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -139.04% 0.00% -301.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.56 -3.12 -3.65 -86 -5.98 119 -5.20 -0.87 -2.84 -4.86
NOPAT Margin		 -6,249.65% -5,577.50% -6,515.00% -151,480.00% -10,482.81% 4,550.42% -9,128.07% -31.99% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.47% -3.56% -5.27% -157.89% -16.31% 215.49% 165.14% -0.27% -18.99% -23.54%
Return On Investment Capital (ROIC_SIMPLE)		 - -29.27% -60.66% 81.83% 293.91% -18,954.05% -86.72% -10.58% -62.45% 91.55%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 4,712.28% 3,721.43% 5,992.86% 3,468.42% 6,105.26% -11.11% 4,831.58% 61.87% 0.00% 0.00%
R&D to Revenue		 4,315.79% 4,346.43% 3,414.29% 213,031.58% 8,970.18% -4,439.31% 4,396.49% 83.83% 0.00% 0.00%
Operating Expenses to Revenue		 9,028.07% 8,067.86% 9,407.14% 216,500.00% 15,075.44% -4,450.42% 9,228.07% 145.70% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.74 -4.46 -4.98 -123 -8.54 146 21 -1.10 -4.06 -7.11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.73 -4.46 -4.98 -123 -8.53 146 21 -1.10 -4.04 -7.06
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.03 1.47 3.53 0.00 0.00 0.00 1.95 1.00 2.88 0.00
Price to Tangible Book Value (P/TBV)		 1.03 1.47 3.53 0.00 0.00 0.00 1.95 1.00 6.62 0.00
Price to Revenue (P/Rev)		 66.03 69.29 93.86 50.01 26.34 3.24 4.18 2.84 4.59 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 1.32 0.43 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 76.03% 230.78% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 21.34 469.18 2.40 1.87 0.00 0.00 2.34 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.60 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.60 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.42 -1.53 -1.75 -1.86 -2.46 -2.45 -2.69 -2.09 -4.71 -27.68
Leverage Ratio		 1.48 1.59 1.84 1.97 2.88 3.32 3.10 2.39 8.51 39.51
Compound Leverage Factor		 1.48 1.97 1.84 1.97 2.88 3.32 3.10 2.39 8.51 39.51
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 1,830.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% -1,730.12% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -23.86 -28.93 -36.84 -66.43 -99.74 -38.76 -41.19 -55.09 -70.86 -114.41
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 446.53% 0.00% 0.00% 0.00% 777.24% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 2.79 2.46 1.93 1.88 1.07 0.72 1.81 2.09 1.22 0.43
Quick Ratio		 2.61 2.26 1.74 1.71 0.90 0.68 1.69 1.96 1.07 0.36
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.08 -3.42 -4.62 -86 -9.26 114 -5.64 -6.84 -8.41 -6.36
Operating Cash Flow to CapEx		 -31,921.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -155.16% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.01 0.01 0.01 0.17 0.15 0.17 0.27 0.00
Accounts Receivable Turnover		 9.83 9.62 12.91 12.91 0.21 1.46 3.34 4.33 1.38 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 8.37 9.83 11.59 14.58 11.89 192.41 206.74 263.91 299.58 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 37.15 37.95 28.26 28.26 1,727.29 249.35 109.33 84.30 263.68 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 37.15 37.95 28.26 28.26 1,727.29 249.35 109.33 84.30 263.68 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -11 -10 -10 -11 -7.44 -4.45 -9.94 -4.82 -1.88 -8.44
Invested Capital Turnover		 -0.02 -0.02 -0.02 -0.02 -0.02 -0.38 -0.27 -0.37 -0.61 0.00
Increase / (Decrease) in Invested Capital		 -1.49 0.30 0.97 0.04 3.28 5.70 0.44 5.97 5.57 1.49
Enterprise Value (EV)		 -10 -5.16 4.82 106 0.54 5.21 -4.27 -4.85 6.65 11
Market Capitalization		 15 16 21 11 5.95 9.03 12 8.24 13 15
Book Value per Share		 $0.69 $0.51 $0.29 ($4.17) ($0.08) ($0.08) $1.98 $1.48 $0.64 ($0.66)
Tangible Book Value per Share		 $0.69 $0.51 $0.29 ($4.17) ($0.08) ($0.40) $1.98 $1.48 $0.28 ($0.98)
Total Capital		 15 11 6.02 6.10 -2.03 -0.63 6.00 8.26 4.55 -5.31
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -25 -21 -16 -17 -5.41 -3.82 -16 -13 -6.42 -3.13
Capital Expenditures (CapEx)		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.59 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.91 -7.38 -7.66 -8.13 -4.84 -6.99 -7.48 -5.06 -4.68 -11
Debt-free Net Working Capital (DFNWC)		 17 13 8.73 8.76 0.58 -3.17 8.46 8.02 1.74 -7.54
Net Working Capital (NWC)		 17 13 8.73 8.76 0.58 -3.17 8.46 8.02 1.74 -7.54
Net Nonoperating Expense (NNE)		 1.18 1.06 1.33 37 2.50 -27 -27 0.04 1.12 2.24
Net Nonoperating Obligations (NNO)		 -25 -21 -16 -17 -5.41 -3.82 -16 -13 -6.42 -3.13
Total Depreciation and Amortization (D&A)		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 -3,498.67% -3,265.93% -3,388.94% -3,595.13% -2,139.38% -250.43% -268.08% -174.41% -164.51% 0.00%
Debt-free Net Working Capital to Revenue		 7,671.24% 5,946.90% 3,863.27% 3,876.55% 254.42% -113.51% 302.94% 276.20% 61.07% 0.00%
Net Working Capital to Revenue		 7,671.24% 5,946.90% 3,863.27% 3,876.55% 254.42% -113.51% 302.94% 276.20% 61.07% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.75) ($124.50) ($6.00) ($121.75) ($8.81) $4.14 $2.17 ($0.11) ($0.34) ($0.53)
Adjusted Weighted Average Basic Shares Outstanding		 840.12K 33.58K 841.74K 1.01M 961.53K 8.23M 6.97M 5.82M 8.82M 10.64M
Adjusted Diluted Earnings per Share		 ($5.75) ($124.50) ($6.00) ($121.75) ($8.81) $4.14 $2.09 ($0.11) ($0.34) ($0.53)
Adjusted Weighted Average Diluted Shares Outstanding		 840.12K 33.58K 841.74K 1.01M 961.53K 8.38M 7.22M 5.82M 8.82M 10.64M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($124.50) $0.00 $0.00 $0.00 $4.14 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 840.14K 0.00 1.01M 1.01M 3.03M 13.81K 14.80K 13.52K 13.47K 13.47K
Normalized Net Operating Profit after Tax (NOPAT)		 -3.56 -3.12 -3.65 -86 -5.98 83 -3.64 -0.87 -2.84 -4.86
Normalized NOPAT Margin		 -6,249.65% -5,577.50% -6,515.00% -151,480.00% -10,482.81% 3,185.29% -6,389.65% -31.99% 0.00% 0.00%
Pre Tax Income Margin		 -8,314.04% -9,882.14% -8,898.21% -216,400.00% -14,975.44% 5,555.69% 37,385.96% -40.36% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.35% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Traws Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Traws Pharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Traws Pharma's net income appears to be on a downward trend, with a most recent value of $9.17 million in 2024, falling from -$63.80 million in 2014. The previous period was -$18.95 million in 2023. View Traws Pharma's forecast to see where analysts expect Traws Pharma to go next.

Traws Pharma's total operating income in 2024 was -$17.88 million, based on the following breakdown:
  • Total Gross Profit: $2.79 million
  • Total Operating Expenses: $20.67 million

Over the last 10 years, Traws Pharma's total revenue changed from $800 thousand in 2014 to $2.79 million in 2024, a change of 248.8%.

Traws Pharma's total liabilities were at $11.25 million at the end of 2025, which was unchanged from 2024, and a 10.8% decrease since 2015.

In the past 10 years, Traws Pharma's cash and equivalents has ranged from $3.82 million in 2024 to $55.07 million in 2021, and is currently $3.82 million as of their latest financial filing in 2025.

Over the last 10 years, Traws Pharma's book value per share changed from 1.05 in 2014 to -0.08 in 2024, a change of -107.5%.


Related Companies

Financial statements for NASDAQ:TRAW last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel